Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsFidelis Care oncology prior auth policy | OpenPaye…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentFidelis CarePolicy N/A

    Oncology medications and supportive agents prior authorization (Wellcare by Fidelis Care)

    Customize your policy alerts

    Sign up for all Fidelis Care policy alerts

    Know when Fidelis Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Requires review by Evolent for oncology medications and supportive agents (medical or pharmacy benefit) for participating providers prior to dispensing or administration for members; includes list of HCPCS/J-codes and oral oncology drugs that require review. Applies to Medicare - Wellcare by Fidelis Care members.

    Policy Summary
    PayerFidelis Care (Wellcare Medicare)
    PolicyOncology medications and supportive agents prior authorization
    Policy CodePolicy N/A
    Change TypeAdministrative — no material clinical or coverage changes
    Effective DateNov 1, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization requests to Evolent via my.newcenturyhealth.com or call 1-888-999-7713 (option 1) and include the entire oncology regimen.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ~400+listed codes & oral agents requiring review
    All agesmember ages
    Participatingprovider submission
    11/1/2025effective

    Coverage Criteria

    Prior authorization / Review requirement

    Covered when ALL of the following are met

    Evolent review required: Request is submitted to Evolent for review prior to dispensing or administration for participating providers via Evolent web portal (my.newcenturyhealth.com) or by phone (1-888-999-7713, option 1)

    Includes medical and pharmacy benefit agents listed; oral agents under J8999 will be processed via pharmacy benefit effective 11/01/2025 for Wellcare by Fidelis Care

    Do NOT submit the following items to Evolent for review: antibiotics; bone marrow, stem cell transplants, and CAR‑T cell therapy; controlled substances (e.g., morphine); equipment requests such as infusion pumps; genetic laboratory testing and laboratory services; hemophilia drugs; inpatient drug requests; inpatient radiation and chemotherapy treatments; iron preparations; radiopharmaceuticals; surgeries/surgical procedures; sickle cell diagnoses and therapies; and immune globulins.

    Coding and Code Lists

    Listed HCPCS/J/Q codes requiring reviewmixedCovered
    C9293GLUCARPIDASE.
    C9306TELISOTUZUMAB VEDOTIN-TLLV.
    J0888
    J0893
    J0894
    J0185APREPITANT INJ (and other mappings shown)
    J0207AMIFOSTINE INJ (and mappings)
    J0208SODIUM THIOSULFATE (and mappings)
    J0594BUSULFAN INJ
    J0641LEVOLEUCOVORIN INJ
    1–10 of 32
    1/4
    Biosimilar preference listingsmixed
    Medical benefitPreferred biosimilars and medical benefit examples (e.g., Retacrit for ESAs; Trazimera for trastuzumab medical benefit; Mvasi/Zirabev for bevacizumab medical benefit; Zarxio for hematopoietic agents).
    Pharmacy benefitPreferred pharmacy benefit agents listed (e.g., Procrit, Herceptin, Avastin, etc.).
    inv-05: Member ages — All ages
    Member agesAll ages
    Applicable settingsPharmacy, physician office, outpatient hospital, ambulatory setting
    Applies toMedicare - Wellcare by Fidelis Care members

    Provider Actions and Submission Requirements

    Prior Authorization

    Evolent prior authorization required

    Prior authorization review by Evolent is required for the listed oncology medications and supportive agents (medical or pharmacy benefit) before they are dispensed or administered for members of all ages. Submit requests via Evolent's web portal or by phone. If you are a non-participating provider, submit requests to the plan via fax (new fax as of 10/1/2023: 1-844-235-5090).

    • Evolent web portal: my.newcenturyhealth.com
    • Evolent phone: 1-888-999-7713, option 1
    • Non-participating provider fax (as of 10/1/2023): 1-844-235-5090
    Prior Authorization

    Oral agents – pharmacy benefit prior authorization

    Effective 11/1/2025, oral oncology agents listed in the policy are processed via the pharmacy benefit and require prior authorization. Providers must submit pharmacy benefit prior authorization requests for oral agents to Evolent for review to establish medical necessity prior to dispensing.

    • This applies to the oral J‑codes and J8999-listed oral agents effective 11/1/2025

    Background

    This policy defines the administrative prior authorization and review workflow for oncology medications and supportive agents: participating providers must submit requests to Evolent for review prior to dispensing or administration so that medically accepted indications and the correct benefit channel (medical vs. pharmacy) can be established. Providers are instructed to submit the entire oncology regimen to Evolent; omitting agents may result in a denial.

    Definitions and Out-of-Scope Items

    inv-12: Out of scope with Evolent — do NOT submit
    Do NOT submit - antibioticsAntibiotics are out of scope and should not be submitted to Evolent
    Do NOT submit - transplants/CAR-TBone marrow, stem cell transplants and CAR‑T cell therapy should NOT be submitted to Evolent
    Do NOT submit - inpatient drug requestsInpatient drug requests and inpatient radiation and chemotherapy treatments are out of scope
    Do NOT submit - equipment & controlled substancesEquipment requests (e.g., infusion pumps) and controlled substances (e.g., morphine) should NOT be submitted to Evolent
    Do NOT submit - genetic testing & lab servicesGenetic lab testing and laboratory services are out of scope and should not be submitted
    Do NOT submit - other exclusionsHemophilia drugs; iron preparations; radiopharmaceuticals; surgeries/surgical procedures; sickle cell diagnoses and therapies; immune globulins are all out of scope

    Step Therapy and Preferred Agents

    Drug class / agentPreferred agent (medical benefit)Preferred agent (pharmacy benefit)Coverage note
    Erythropoiesis‑stimulating agentsRetacrit (if unavailable due to shortage: Epogen)ProcritPreferred agents listed; submit preferred agent to Evolent for review prior to dispensing or administration
    Trastuzumab (HER2)TrazimeraHerceptin; Herceptin Hylecta; Herzuma; Kanjinti; Ogivri; Ontruzant; TrazimeraPreferred agents listed by benefit channel; submit for Evolent review
    BevacizumabMvasi; ZirabevAvastin; Mvasi; ZirabevPreferred agents listed by benefit channel; submit for Evolent review
    RituximabRuxience; TruximaRiabni; Rituxan; Rituxan Hycela; Ruxience; TruximaPreferred agents listed by benefit channel; submit for Evolent review
    Hematopoietic agentsZarxioZarxioPreferred agent for medical & pharmacy benefit; submit for Evolent review
    Bone agentszoledronic acid; pamidronatezoledronic acid; pamidronate; Prolia; Xgeva; risedronate; ibandronatePreferred agents listed by benefit channel; submit for Evolent review

    Site of Care Requirements

    Note

    Review required by site of care

    Evolent review is required prior to dispensing at a pharmacy or administering in a physician office, infusion center, or outpatient hospital/ambulatory setting for members of all ages.

    • Applies to pharmacy, office/clinic, home infusion, infusion center, and hospital outpatient settings.

    Biosimilar Guidance

    Billing Rule

    Retacrit preferred (Epogen alternative if unavailable)

    For erythropoiesis‑stimulating agents, Retacrit is the preferred medical‑benefit product; Epogen may be used if Retacrit is unavailable due to shortage.

    Billing Rule

    Trastuzumab biosimilar preferences — Trazimera preferred (medical)

    For trastuzumab, Trazimera is the preferred medical‑benefit agent; multiple trastuzumab biosimilars are listed for the pharmacy benefit and should be submitted to Evolent for review.

    • Medical benefit preferred: Trazimera
    • Pharmacy benefit examples: Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera

    Revision History

    2025-11-01policy_effective_dateLatest

    Oral oncology agents listed (many billed under J8999) will be processed via the pharmacy benefit and require prior review by Evolent for Wellcare by Fidelis Care members starting 11/1/2025.

    Policy Summary
    PayerFidelis Care (Wellcare Medicare)
    PolicyOncology medications and supportive agents prior authorization
    Policy CodePolicy N/A
    Change TypeAdministrative — no material clinical or coverage changes
    Effective DateNov 1, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization requests to Evolent via my.newcenturyhealth.com or call 1-888-999-7713 (option 1) and include the entire oncology regimen.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Code ListsProvider Actions and Submission RequirementsBackgroundDefinitions and Out-of-Scope ItemsStep Therapy and Preferred AgentsSite of Care RequirementsBiosimilar GuidanceRevision History
  1. Examples: capecitabine, etoposide (oral), temozolomide, many targeted oral agents (see full list in policy)
  2. Documentation Required

    Regimen submission required

    Submit the entire oncology regimen to Evolent for review, regardless of whether individual agents appear to require prior authorization. Omitting elements of the regimen may result in denial of the request. Certain items are out of scope and should NOT be submitted to Evolent (see list).

    • Do submit the full regimen (all agents, doses, schedule, and supportive care) with each request
    • Do NOT submit the following to Evolent: antibiotics; bone marrow/stem cell transplants and CAR‑T; controlled substances; equipment requests; genetic lab testing and laboratory services; hemophilia drugs; inpatient drug requests; inpatient radiation and chemotherapy; iron preparations; radiopharmaceuticals; surgeries/surgical procedures; sickle cell diagnoses and therapies; immune globulins
    • Preferred biosimilar agents are listed in the policy — preferred agents should still be sent to Evolent for review
    Note

    Biosimilar preference note

    Preferred biosimilar agents for oncology-related indications are identified in the policy. Providers should still include these agents when submitting the regimen to Evolent for review.

    • Erythropoiesis‑stimulating agents: Medical benefit Retacrit (Epogen if shortage); Pharmacy benefit Procrit
    • Trastuzumab: Medical benefit Trazimera; Pharmacy benefit Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera
    • Bevacizumab: Medical benefit Mvasi, Zirabev; Pharmacy benefit Avastin, Mvasi, Zirabev
    • Hematopoietic agents: Medical & Pharmacy benefit Zarxio
    • Rituximab: Medical benefit Ruxience, Truxima; Pharmacy benefit Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima
    Billing Rule

    Bevacizumab/Avastin — preferred agents by benefit; review required

    Bevacizumab/Avastin preferences are listed by benefit channel (e.g., Mvasi, Zirabev for medical benefit; Avastin, Mvasi, Zirabev for pharmacy benefit); these agents still require Evolent review.

    • Medical benefit preferred: Mvasi, Zirabev
    • Pharmacy benefit examples: Avastin, Mvasi, Zirabev